Third Arc Bio
$165.0M
Funding date
Valuation / Funding
No funding history available
Funding data has not been imported for this company yet
Current Valuation Metrics
Third Arc Bio is currently valued at $315.0M as of July 23, 2024. The company has raised a total of $197.7M in funding.
Capital Efficiency
With a capital efficiency ratio of 1.59x, Third Arc Bio has achieved a valuation that is 1.59 times the total capital raised. This metric indicates room for improvement in capital deployment.
Investment Perspective
Third Arc Bio's valuation reflects investor confidence in the company's market position, growth potential, and ability to execute on its business model. Private market valuations are determined by primary funding rounds and secondary market transactions, which take into account financial performance, market conditions, and growth prospects.
What is Third Arc Bio Worth in 2025?
As of 2025, Third Arc Bio is valued at $315.0M, based on the company's Early Stage VC funding round in July 23, 2024. This valuation positions Third Arc Bio as one of the leading private companies in the sector.
Third Arc Bio Valuation History
Third Arc Bio's funding history demonstrates steady growth and investor confidence.
How Third Arc Bio Valuation is Determined
Private company valuations like Third Arc Bio's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including:
- Revenue growth and financial performance
- Market opportunity and total addressable market (TAM)
- Competitive positioning and market share
- Management team strength and execution capability
- Technology and intellectual property
- Industry trends and investor sentiment
Third Arc Bio Valuation FAQs
Is Third Arc Bio profitable?
Third Arc Bio has not publicly disclosed its profitability status. Many high-growth private companies prioritize market expansion and user growth over profitability in their early stages.
How does Third Arc Bio's valuation compare to competitors?
Third Arc Bio is valued at $315.0M, positioning it as a major player in the space. Secondary market pricing and private market transactions provide ongoing validation of this valuation.
When will Third Arc Bio IPO?
Third Arc Bio has not announced plans for an initial public offering. Until an IPO, investors can access Third Arc Bio shares through secondary market platforms.